This is the authors' abstract. We don't add key points for this paper.
We found that omalizumab reduced viable cell numbers but this was not through induction of apoptosis. IL-4R and germline Cϵ mRNA levels were decreased as well as the number of membrane IgE+ cells in B cells treated with omalizumab. These data suggest that omalizumab may decrease IgE synthesis by human B cells by specifically targeting membrane IgE-bearing B cells and inducing a state of anergy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: